1,812
Views
12
CrossRef citations to date
0
Altmetric
Reviews

Prophylactic vaccinations in chronic kidney disease: Current status

Pages 2599-2605 | Received 20 Jan 2015, Accepted 22 Mar 2015, Published online: 14 Sep 2015

References

  • Neovius M, Jacobson SH, Eriksson JK, Elinder CG, Hylander B. Mortality in chronic kidney disease and renal replacement therapy: a population-based cohort study. BMJ Open 2014; 4: e004251; PMID:24549162; http://dx.doi.org/10.1136/bmjopen-2013-004251
  • Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R, et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 2014; 383: 1831-43; PMID:24856028; http://dx.doi.org/10.1016/S0140-6736(14)60384-6
  • Kalia H, Fabrizi F, Martin P. Hepatitis B virus and renal transplantation. Transplant Rev (Orlando) 2011; 25: 102-9; PMID:21530218; http://dx.doi.org/10.1016/j.trre.2011.02.001
  • Vermeiren AP, Hoebe CJ, Dukers-Muijrers NHJ. High non-responsiveness of males and the elderly to standard hepatitis B vaccination among a large cohort of healthy employees. Clin Virol 2013; 58: 262-4; http://dx.doi.org/10.1016/j.jcv.2013.07.003
  • Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33: 492-503; PMID:21029960; http://dx.doi.org/10.1016/j.immuni.2010.10.002
  • Cruz LJ, Tacken PJ, Rueda F, Domingo JC, Albericio F, Figdor CG. Targeting nanoparticles to dendritic cells for immunotherapy. Methods Enzymol 2012; 509: 143-63; PMID:22568905; http://dx.doi.org/10.1016/B978-0-12-391858-1.00008-3
  • Grzegorzewska AE. Hepatitis B vaccination in chronic kidney disease: review of evidence in non-dialyzed patients. Hepat Mon 2012; 12: e7359; PMID:23326280; http://dx.doi.org/10.5812/hepatmon.7359
  • Grzegorzewska AE. Hepatitis B vaccination in chronic kidney disease patients: a call for novel vaccines. Expert Rev Vaccines 2014; 13: 1317-26; PMID:25148051; http://dx.doi.org/10.1586/14760584.2014.944508
  • Mathew R, Mason D, Kennedy JS. Vaccination issues in patients with chronic kidney disease. Expert Rev Vaccines 2014; 13: 285-98; PMID:24405403; http://dx.doi.org/10.1586/14760584.2014.874950
  • Vaziri ND, Pahl MV, Crum A, Norris K. Effect of uremia on structure and function of immune system. J Ren Nutr 2012; 22: 149-56; PMID:22200433; http://dx.doi.org/10.1053/j.jrn.2011.10.020
  • Geara AS, Castellanos MR, Bassil C, Schuller-Levis G, Park E, Smith M, Goldman M, Elsayegh S. Effects of parathyroid hormone on immune function. See comment in PubMed Commons belowClin Dev Immunol 2010; 2010: pii: 418695
  • Brigotti M, Carnicelli D, Arfilli V, Tamassia N, Borsetti F, Fabbri E, Tazzari PL, Ricci F, Pagliaro P, Spisni E, et al. Identification of TLR4 as the receptor that recognizes Shiga toxins in human neutrophils. See comment in PubMed Commons belowJ Immunol 2013; 191: 4748-58; PMID:24068665
  • Gollapudi P, Yoon JW, Gollapudi S, Pahl MV, Vaziri ND. Leukocyte toll-like receptor expression in end-stage kidney disease. Am J Nephrol 2010; 31: 247-54; PMID:20090311; http://dx.doi.org/10.1159/000276764
  • Wang ZS, Xu DM, Guan GJ, Cui MY, Wei Y, Tang LJ, Jia XY, Li WB. [Clinical significance of toll-like receptor 4 expression on the surface of peripheral blood mononuclear cells in uremic patients]. [Article in Chinese] Zhonghua Yi Xue Za Zhi 2010; 90: 2389-91
  • Yang M, Gan H, Shen Q, Tang W, Du X, Chen D. Proinflammatory CD14+CD16+ monocytes are associated with microinflammation in patients with type 2 diabetes mellitus and diabetic nephropathy uremia. Inflammation 2012; 35: 388-96; PMID:21847775; http://dx.doi.org/10.1007/s10753-011-9374-9
  • Vallés PG, Melechuck S, González A, Manucha W, Bocanegra V, Vallés R. Toll-like receptor 4 expression on circulating leucocytes in hemolytic uremic syndrome. Pediatr Nephrol 2012; 27: 407-15; http://dx.doi.org/10.1007/s00467-011-2014-7
  • Zhou ZX, Zhang J, Sun L. C7: a CpG oligodeoxynucleotide that induces protective immune response against megalocytivirus in Japanese flounder (Paralichthys olivaceus) via Toll-like receptor 9-mediated signaling pathway. Dev Comp Immunol 2014; 44: 124-32; PMID:24333437; http://dx.doi.org/10.1016/j.dci.2013.12.002
  • Chua BY, Johnson D, Tan A, Earnest-Silveira L, Sekiya T, Chin R, Torresi J, Jackson DC. Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses. PLoS One 2012; 7: e47492; PMID:23091628; http://dx.doi.org/10.1371/journal.pone.0047492
  • Kim KW, Chung BH, Jeon EJ, Kim BM, Choi BS, Park CW, Kim YS, Cho SG, Cho ML, Yang CW. B cell-associated immune profiles in patients with end-stage renal disease (ESRD). Exp Mol Med 2012; 44: 465-72; PMID:22617684; http://dx.doi.org/10.3858/emm.2012.44.8.053
  • Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, Vaziri ND. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant 2010; 25: 205-12; PMID:19684120; http://dx.doi.org/10.1093/ndt/gfp397
  • Zhou L, Sun L, Wu H, Zhang L, Chen M, Liu J, Zhong R. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF). Eur J Pharmacol 2013; 715: 230-7; PMID:23712004; http://dx.doi.org/10.1016/j.ejphar.2013.05.016
  • Lin SY, Liu JH, Wang SM, Wang IK, Tsai CA, Liu YL, Lin HH, Chang CC, Huang CC. Association of response to hepatitis B vaccination and survival in dialysis patients. BMC Nephrol 2012; 13: 97; PMID:22935561; http://dx.doi.org/10.1186/1471-2369-13-97
  • Brown CM, Donlon S, O'Kelly P, Casey AM, Collier C, Conlon PJ, Walshe JJ. A prospective study of hepatitis B vaccination - a comparison of responders versus nonresponders. Ren Fail 2011; 33: 276-9; PMID:21401350; http://dx.doi.org/10.3109/0886022X.2011.559300
  • Al Saran K, Sabry A, Al Halawany Z, Ismail M. Factors affecting response to hepatitis B vaccine among hemodialysis patients in a large Saudi Hemodialysis Center. Saudi J Kidney Dis Transpl 2014; 25: 185-91; PMID:24434410; http://dx.doi.org/10.4103/1319-2442.124572
  • Grzegorzewska AE, Wobszal P, Jagodziński PP. Interleukin-18 promoter polymorphism and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients. Kidney Blood Press Res. 2012; 35: 1-8; PMID:21832842; http://dx.doi.org/10.1159/000329932
  • Grzegorzewska AE, Wobszal PM, Mostowska A, Jagodziński PP. Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients. BMC Nephrol 2012; 13: 75; PMID:22863216; http://dx.doi.org/10.1186/1471-2369-13-75
  • Grzegorzewska AE, Wobszal PM, Sowińska A, Mostowska A, Jagodziński PP. Association of the interleukin-12 polymorphic variants with the development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to vaccination or infection. Mol Biol Rep 2013; 40: 6899-911; PMID:24158609; http://dx.doi.org/10.1007/s11033-013-2809-7
  • Grzegorzewska AE, Pajzderski D, Sowińska A, Mostowska A, Jagodziński PP. IL4R and IL13 polymorphic variants and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to HBV vaccination or infection. Vaccine 2013; 31: 1766-70; PMID:23462527; http://dx.doi.org/10.1016/j.vaccine.2013.02.023
  • Grzegorzewska AE, Pajzderski D, Sowińska A, Jagodziński PP. Polymporphism of monocyte chemoattractant protein 1 (MCP1 –2518 A/G) and responsiveness to hepatitis B vaccination in hemodialysis patients. Pol Arch Med Wewn 2014; 124: 10-8; PMID:24382482
  • Grzegorzewska AE, Pajzderski D, Sowińska A, Jagodziński PP. Monocyte chemoattractant protein-1 gene (MCP-1-2518 A/G) polymorphism and serological markers of hepatitis B virus infection in hemodialysis patients. Med Sci Monit 2014; 20: 1101-16; PMID:24975639; http://dx.doi.org/10.12659/MSM.891009
  • Zitt E, Sprenger-Mähr H, Knoll F, Neyer U, Lhotta K. Vitamin D deficiency is associated with poor response to active hepatitis B immunisation in patients with chronic kidney disease. Vaccine 2012; 30: 931-5; PMID:22142584; http://dx.doi.org/10.1016/j.vaccine.2011.11.086
  • Grzegorzewska AE, Jodłowska E, Mostowska A, Sowińska A, Jagodziński PP. Single nucleotide polymorphisms of vitamin D binding protein, vitamin D receptor and retinoid X receptor α genes and response to hepatitis B vaccination in renal replacement therapy patients. Expert Rev Vaccines 2014; 13: 1395-403; PMID:25245883; http://dx.doi.org/10.1586/14760584.2014.962521
  • Duranti E, Duranti D. Polymethylmethacrylate strengthens antibody response in hemodialysis patients not responding to hepatitis B vaccine: preliminary data. Minerva Med 2011; 102: 469-74; PMID:22193378
  • Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 1-150; http://dx.doi.org/10.1038/kisup.2012.73
  • Recommended Adult Immunization Schedule — United States – 2015. http://www.cdc.gov/vaccines/schedules/hcp/imz/adult-conditions.html. Accessed February 22, 2015)
  • Ghadiani MH, Besharati S, Mousavinasab N, Jalalzadeh M. Response rates to HB vaccine in CKD stages 3–4 and hemodialysis patients. J Res Med Sci 2012; 17: 527-33; PMID:23626628
  • Roznovský L, Tvrdík J, Kabieszová L, Petrousová L, Orságová I, Hozáková L, Lochman I, Kloudová A, Valkovský I, Letocha P, et al. [Vaccination against hepatitis B in patients with chronic renal failure–twenty years follow-up]. [Article in Czech] Vnitr Lek 2011; 57: 808-14
  • Sawyer MH, Hoerger TJ, Murphy TV, Schillie SF, Hu D, Spradling PR, Byrd KK, Xing J, Reilly ML, Tohme RA, Moorman A, Smith EA, Baack BN, Jiles RB, Klevens M, Ward JW, Kahn HS, Zhou F. Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep 2011; 60: 1709-25; PMID:22189894
  • US. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013; http://www.usrds.org/atlas.aspx
  • Garçon N. Preclinical development of AS04. Methods Mol Biol 2010; 626: 15-27; http://dx.doi.org/10.1007/978-1-60761-585-9_2
  • Polito P, Di Lullo L, Iannacci GR, Cecilia A, Galderisi C, Gorini A. [Seroconversion and immune response after anti-HBV vaccination in patients on chronic hemodialysis: comparison of two vaccines]. [Article in Italian] G Ital Nefrol 2011; 28: 525-30
  • Hoebe CJ, Vermeiren AP, Dukers-Muijrers NH. Revaccination with Fendrix® or HBVaxPro® results in better response rates than does revaccination with three doses of Engerix-B® in previous non-responders. Vaccine 2012; 30: 6734-7; PMID:22981848; http://dx.doi.org/10.1016/j.vaccine.2012.08.074
  • Beran J, Hobzova L, Wertzova V, Kuriyakose S, Leyssen M, Surquin M, Houard S. Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. Hum Vaccin 2010; 6: 578-84; PMID:20523113; http://dx.doi.org/10.4161/hv.6.7.11883
  • Tielemans CL, Vlasak J, Kosa D, Billiouw JM, Verpooten GA, Mezei I, Ryba M, Peeters PC, Mat O, Jadoul MY, et al. Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials. Vaccine 2011; 29: 1159-66; PMID:21167859; http://dx.doi.org/10.1016/j.vaccine.2010.12.009
  • Surquin M, Tielemans CL, Kulcsár I, Ryba M, Vörös P, Mat O, Treille S, Dhaene M, Stolear JC, Kuriyakose SO, et al. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine. Kidney Int 2010; 77: 247-55; PMID:19940840; http://dx.doi.org/10.1038/ki.2009.454
  • Surquin M, Tielemans C, Nortier J, Jadoul M, Peeters P, Ryba M, Roznovsky L, Domán J, Barthelemy X, Crasta PD, et al. Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency. Hum Vaccin 2011; 7: 913-8; PMID:21892006; http://dx.doi.org/10.4161/hv.7.9.16225
  • Heplisav approval status. http://www.drugs.com/history/heplisav.html. Accessed February 23, 2015
  • Halperin SA, Ward B, Cooper C, Predy G, Diaz-Mitoma F, Dionne M, Embree J, McGeer A, Zickler P, Moltz KH, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age. Vaccine 2012; 30: 2556-63; PMID:22326642; http://dx.doi.org/10.1016/j.vaccine.2012.01.087
  • Halperin SA, McNeil S, Langley JM, Smith B, MacKinnon-Cameron D, McCall-Sani R, Heyward WL, Martin JT. Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults. Vaccine 2012; 30: 5445-8; PMID:22704926; http://dx.doi.org/10.1016/j.vaccine.2012.05.074
  • Halperin SA, Ward BJ, Dionne M, Langley JM, McNeil SA, Smith B, Mackinnon-Cameron D, Heyward WL, Martin JT. Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine. Hum Vaccin Immunother 2013; 9: 1438-44; PMID:23571179; http://dx.doi.org/10.4161/hv.24256
  • Sablan BP, Kim DJ, Barzaga NG, Chow WC, Cho M, Ahn SH, Hwang SG, Lee JH, Namini H, Heyward WL. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine 2012; 30: 2689-96; PMID:22342916; http://dx.doi.org/10.1016/j.vaccine.2012.02.001
  • Heyward WL, Kyle M, Blumenau J, Davis M, Reisinger K, Kabongo ML, Bennett S, Janssen RS, Namini H, Martin JT. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age. Vaccine 2013; 31: 5300-5; PMID:23727002; http://dx.doi.org/10.1016/j.vaccine.2013.05.068
  • Janssen RS, Mangoo-Karim R, Pergola PE, Girndt M, Namini H, Rahman S, Bennett SR, Heyward WL, Martin JT. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. Vaccine 2013; 31: 5306-13; PMID:23727422; http://dx.doi.org/10.1016/j.vaccine.2013.05.067
  • Halperin SA, Ward BJ, Dionne M, Langley JM, McNeil SA, Smith B, Mackinnon-Cameron D, Heyward WL, Martin JT. Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine. Hum Vaccin Immunother 2013; 9: 1438-44; PMID:23571179; http://dx.doi.org/10.4161/hv.24256
  • Kuan RK, Janssen R, Heyward W, Bennett S, Nordyke R. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine. Vaccine 2013; 31: 4024-32; PMID:23707166; http://dx.doi.org/10.1016/j.vaccine.2013.05.014
  • Di Pasquale A, De Ridder M, Van Der Meeren O. Hepatitis B virus vaccine in chronic kidney diseases: improved immunogenicity by adjuvants? Limits of a meta-analysis. Vaccine 2012; 30: 5586; PMID:22749597; http://dx.doi.org/10.1016/j.vaccine.2012.06.023
  • Saade F, Honda-Okubo Y, Trec S, Petrovsky N. A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine 2013; 31: 1999-2007; PMID:23306367; http://dx.doi.org/10.1016/j.vaccine.2012.12.077
  • Fakharzadeh S, Kalanaky S, Hafizi M, Goya MM, Masoumi Z, Namaki S, Shakeri N, Abbasi M, Mahdavi M, Nazaran MH. The new nano-complex, Hep-c, improves the immunogenicity of the hepatitis B vaccine. Vaccine 2013; 31: 2591-7; PMID:23583463; http://dx.doi.org/10.1016/j.vaccine.2013.03.030
  • Gray PM, Forrest G, Wisniewski T, Porter G, Freed DC, DeMartino JA, Zaller DM, Guo Z, Leone J, Fu TM, et al. Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities. Cell Immunol 2012; 278: 113-9; PMID:23121983; http://dx.doi.org/10.1016/j.cellimm.2012.07.006
  • Chen X, Zhang W, Gao W, Zou Q, Feng C, Liu H, Zhou C, Zhang Y, Wang B. Hemokinin-1 as an adjuvant molecule enhancing humoral and memory responses to HBsAg DNA vaccination. Viral Immunol 2012; 25: 289-96; PMID:22876773; http://dx.doi.org/10.1089/vim.2012.0015
  • Sanadgol H. Levamisole usage as an adjuvant to hepatitis B vaccine in hemodialysis patients, yes or no? Nephrourol Mon 2013; 5: 673-8; PMID:23577329; http://dx.doi.org/10.5812/numonthly.3985
  • Afsharian M, Vaziri S, Janbakhsh AR, Sayad B, Mansouri F, Nourbakhsh J, Qadiri K, Najafi F, Shirvanii M. The effect of zinc sulfate on immunologic response to recombinant hepatitis B vaccine in elderly: Zinc sulfate and immunologic response to recombinant hepatitis B vaccine. Hepat Mon 2011; 11: 32-5; PMID:22087114
  • Janbakhsh A, Mansouri F, Vaziri S, Sayad B, Afsharian M, Rahimi M, Shahebrahimi K, Salari F. Effect of selenium on immune response against hepatitis B vaccine with accelerated method in insulin-dependent diabetes mellitus patients. Caspian J Intern Med 2013; 4: 603-6; PMID:24009944
  • Mbaeyi C, Thompson ND. Hepatitis C Virus Screening and Management of Seroconversions in Hemodialysis Facilities. Seminar Dial 2013; 26: 439-46; http://dx.doi.org/10.1111/sdi.12097
  • Fauvelle C, Lepiller Q, Felmlee DJ, Fofana I, Habersetzer F, Stoll-Keller F, Baumert TF, Fafi-Kremer S. Hepatitis C virus vaccines - progress and perspectives. Microb Pathog 2013; 58: 66-72; PMID:23499591; http://dx.doi.org/10.1016/j.micpath.2013.02.005
  • Tung J, Carlisle E, Smieja M, Kim PT, Lee CH. A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients. Am J Kidney Dis 2010; 56: 713-9; PMID:20630640; http://dx.doi.org/10.1053/j.ajkd.2010.04.015
  • Beaumont E, Patient R, Hourioux C, Dimier-Poisson I, Roingeard P. Chimeric HBV-HCV envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine. Hepatology 2012; ; http://dx.doi.org/10.1002/hep.26132
  • Baker C, Pickering L, Chilton L, Cieslak P, Ehresmann K, Englund J, Judson F, Keitel W, Lett S, Marcy M, et al. General recommendations on immunization - recommendations of the Advisory Committee on Immunization Practices (ACIP). National Center for Immunization and Respiratory Diseases. MMWR Recomm Rep 2011; 60: 1-64
  • Wang IK, Lin CL, Lin PC, Liang CC, Liu YL, Chang CT, Yen TH, Morisky DE, Huang CC, Sung FC. Effectiveness of influenza vaccination in patients with end-stage renal disease receiving hemodialysis: a population-based study. PLoS One 2013; 8: e58317
  • McGrath LJ, Cole SR, Kshirsagar AV, Weber DJ, Stürmer T, Brookhart MA. Hospitalization and skilled nursing care are predictors of influenza vaccination among patients on hemodialysis: evidence of confounding by frailty. Med Care 2013; 51: 1106-13; PMID:23969584; http://dx.doi.org/10.1097/MLR.0b013e3182a50297
  • Wilmore SM, Philip KE, Cambiano V, Bretherton CP, Harborne JE, Sharma A, Jayasena SD. Influenza and pneumococcal vaccinations in dialysis patients in a London district general hospital. Clin Kidney J 2014; 7: 27-32; PMID:24466425; http://dx.doi.org/10.1093/ckj/sft138
  • Kumar D, Morris MI, Kotton CN, Fischer SA, Michaels MG, Allen U, Blumberg EA, Green M, Humar A, Ison MG. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant 2010; 10: 18-25; PMID:19958321; http://dx.doi.org/10.1111/j.1600-6143.2009.02960.x
  • Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011; 29: 2461-73; PMID:21256188; http://dx.doi.org/10.1016/j.vaccine.2011.01.011
  • Langley JM, Risi G, Caldwell M, Gilderman L, Berwald B, Fogarty C, Poling T, Riff D, Baron M, Frenette L, et al. Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A phase III, placebo-controlled, randomized study. J Infect Dis 2011; 203: 1729-38; PMID:21606531; http://dx.doi.org/10.1093/infdis/jir172
  • Broeders NE, Hombrouck A, Lemy A, Wissing KM, Racapé J, Gastaldello K, Massart A, Van Gucht S, Weichselbaum L, De Mul A, et al. Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. Clin J Am Soc Nephrol 2011; 6: 2573-8; PMID:21921153; http://dx.doi.org/10.2215/CJN.04670511
  • Labriola L, Hombrouck A, Marechal C, Van GS, Brochier B, Thomas I, Jadoul M, Goubau P. Immunogenicity of an adjuvanted 2009 pandemic influenza A (H1N1) vaccine in haemodialysed patients. Nephrol Dial Transplant 2011; 26: 1424-28; PMID:21273236; http://dx.doi.org/10.1093/ndt/gfq782
  • Brakemeier S, Schweiger B, Lachmann N, Glander P, Schonemann C, Diekmann F, Neumayer HH, Budde K. Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix®) in renal transplant recipients. Nephrol Dial Transplant 2012; 27: 423-8; PMID:21613386; http://dx.doi.org/10.1093/ndt/gfr278
  • Dikow R, Eckerle I, Ksoll-Rudek D, Hampel H, Schwenger V, Zeier M, Schnitzler P, Sommerer C. Immunogenicity and Efficacy in Hemodialysis Patients of an AS03A-Adjuvanted Vaccine for 2009 Pandemic Influenza A(H1N1): A Nonrandomized Trial. Am J Kidney Dis 2011; 57: 716-23; PMID:21349617
  • Esposito S, Mastrolia MV, Ghio L, Paglialonga F, Terranova L, Scala A, Edefonti A, Principi N. Influenza immunization in hemodialyzed or kidney transplanted adolescents and young adults. Expert Rev Vaccines 2014; 13: 1059-66; PMID:24972949
  • Azak A, Huddam B, Kocak G, Altas AB, Duranay M, Korukluoglu G. Antibody response after single H1N1 influenza vaccine in chronic dialysis patients. Ther Apher Dial 2013; 17: 55-9; PMID:23379494
  • Quintana LF, Serra N, De Molina-Llauradó P, Blasco M, Martinez M, Campos B, Bayas JM, Pumarola T, Campistol JM. Influence of renal replacement therapy on immune response after one and two doses of the A(H1N1) pdm09 vaccine. Influenza Other Respir Viruses 2013; 7: 809-14; PMID:23078139
  • Moon SJ, Lee SH, Byun YH, Yun GY, Kim SK, Seong BL, Kim AR, Sun Park E, Kim HJ, Lee JE, et al. Risk factors affecting seroconversion after influenza A/H1N1 vaccination in hemodialysis patients. BMC Nephrol 2012; 13: 165; PMID:23206898
  • Bond TC, Spaulding AC, Krisher J, McClellan W. Mortality of dialysis patients according to influenza and pneumococcal vaccination status. Am J Kidney Dis 2012; 60: 959-65; PMID:22694948
  • Duggal T, Segal P, Shah M, Carter-Monroe N, Manoharan P, Geetha D. Antineutrophil cytoplasmic antibody vasculitis associated with influenza vaccination. Am J Nephrol 2013; 38: 174-8; PMID:23941822
  • Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61: 816-9; PMID:23051612; http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm
  • Gilbertson DT, Guo H, Arneson TJ, Collins AJ. The association of pneumococcal vaccination with hospitalization and mortality in hemodialysis patients. Nephrol Dial Transplant 2011; 26: 2934-9; PMID:21317410
  • Bitsaktsis C, Iglesias BV, Li Y, Colino J, Snapper CM, Hollingshead SK, Pham G, Gosselin DR, Gosselin EJ. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity. Infect Immun 2012; 80: 1166-80; PMID:22158740

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.